TX-PANDA-BIOTECH
3.4.2024 15:01:28 CEST | Business Wire | Press release
Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500,000-square-foot building situated on 97 acres is the first of its kind and the largest in the Western Hemisphere, with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. It is a zero-waste process, utilizing every part of the industrial hemp stalk, and operates solely on 100 percent renewable energy, making it a paragon of sustainability in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403426324/en/
Panda Hemp Gin is a 500,000-square-foot building situated on 97 acres with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. (Photo: Business Wire)
The Panda Hemp Gin is fully operational, and production will continue to ramp up in the coming months. In February, the complex commissioning process of Panda's 600-yard-long processing line and three miles of overhead pneumatic duct lines, including each piece of equipment for decortication, refining, blending, mechanical cottonization, hurd bagging and storage, and baling, was successfully completed.
"Panda Biotech's state-of-the-art industrial hemp processing facility is a monumental achievement and a game-changer for both agriculture and industry,” said Dixie Carter, president of Panda Biotech. “As research and development in this area continue to advance, industrial hemp fiber and cellulose will help transform numerous industries with sustainable goals and challenges. Panda’s industrial hemp will play a pivotal role in satisfying significant global market demand for renewable processes and products.”
Industrial hemp is considered one of the most versatile raw materials available with an unmatched variety of potential uses. The Panda Hemp Gin will focus on providing five main product lines from hemp, including mechanically cottonized fiber, decorticated fiber, hurd (cellulose), short-fiber/hurd mix, and nutrient-rich micronized hemp dust. The innumerous applications for each product vary broadly from consumer and industrial textiles, non-wovens, paper products, bioplastics, biofuel, animal bedding, fiberglass substitute, construction materials such as hempcrete, mulch, insulation, and more.
With a commitment to traceability and processing only U.S.-grown hemp straw, as well as providing an astounding pay-to-grow program, Panda’s partnership with the American farming community is at the heart of the operation. Industrial hemp provides a multitude of benefits for producers, as it is scientifically proven to minimize CO2 emissions, absorbing more per acre than any forest or commercial crop. Additionally, hemp requires significantly less water than most major crops, provides outstanding soil remediation, and requires minimal fertilizers, pesticides, and herbicides. Panda is actively contracting with producers for its pay-to-grow program for this harvest and with farmers who may have straw or fiber from previous harvests or the 2024 growing season. Interested producers can reach out to Panda through the website at pandabiotech.com.
"The massive scale of the campus, allowing more than 22,000 pounds of baled hemp straw for processing per hour, is what makes this industrial hemp processing facility unique,” said Scott Evans, chief operating officer of Panda Biotech. “Our straw is sourced directly from our farming partners in Texas and surrounding states, and, through our decortication process, it is transformed into packaged products, ready for retail or downstream manufacturing applications, within minutes. Panda's processing equipment and infrastructure is truly best-in-class."
For more information, please visit www.pandabiotech.com and follow us at @pandabiotech on Facebook, Instagram, X, and LinkedIn.
ABOUT PANDA BIOTECH
Based in Dallas, Texas, privately-held Panda Biotech, LLC is a first-mover in the emerging U.S. industrial hemp fiber and hurd industry that is 100 percent American-owned, grown, and processed. Panda Biotech’s executive leadership has extensive experience developing, financing, constructing, and operating large-scale infrastructure facilities in clean energy. They have developed 22 projects representing approximately $12 billion in invested capital. Panda Biotech’s first project, the Panda Hemp Gin™, is in partnership with Aka-Ag, LLC, a wholly-owned subsidiary of the Southern Ute Indian Tribe Growth Fund. The facility is located in Wichita Falls, Texas. It is the largest industrial hemp processing facility of its kind in the Western Hemisphere.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403426324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
